Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 145 of 6351
-
Heart showdown: which diabetes drug shields the heart better?
Disease control CompletedThe purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can an immunotherapy combo shrink stomach tumors before surgery?
Disease control CompletedGastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis rate. Studies have shown that patients with good patho…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Promising combo tackles aggressive lymphoma in large trial
Disease control CompletedTucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin…
Phase 3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy plus chemoradiation may help bladder cancer patients keep their bladder
Disease control OngoingResearchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body. MIBC is treated by having surgery to remove the bladder (cystectomy). Not all people choo…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Cooling duration may be key to brain recovery after cardiac arrest
Disease control CompletedA multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comato…
Sponsor: University of Michigan • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Double-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufact…
Phase 1/2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Immunotherapy boosts standard treatment for advanced cervical cancer
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus con…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for Tough-to-Treat myeloma: DREAMM 7 trial tests powerful combo
Disease control OngoingThis is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurren…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for endometrial cancer: immunotherapy and targeted drug combo tested
Disease control OngoingA study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immunotherapy combo aims to extend life in stage 3 lung cancer
Disease control OngoingThis phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies,…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Stem cell infusion may help severely ill COVID-19 patients breathe
Disease control Stopped earlyMulticenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to pat…
Phase 2/3 • Sponsor: Healios K.K. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Three-Drug cocktail boost Radiation's power against a rare lymphoma?
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of camrelizumab, apatinib, pegaspargase (CAPA) and as an intruction immunotherapy with radiotherapy as first-line treatment in patients with de novo stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type…
Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for bile duct cancer: liver transplant after Chemo-Radiation
Disease control Recruiting nowA prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radiochemotherapy will…
Sponsor: Hospital Vall d'Hebron • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Blood test could catch colon Cancer's return before it starts
Disease control OngoingThis research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatme…
Phase 3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Surgery may give paralyzed patients a helping hand
Disease control OngoingCurrent treatment strategies of acute cervical spinal cord injuries remain limited. Treatment options that provide meaningful improvements in patient quality of like and long-term functional independence will provide a significant public health impact. Specific aim: Measure the e…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an immunotherapy combo shrink lung tumors before surgery? a phase 3 trial aims to find out.
Disease control CompletedThis is a randomized, double-blind, placebo-controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy versus placebo combined with platinum-based doublet drug chem…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart returning leukemia?
Disease control CompletedThis is an open-label Phase I dose-escalation study of oral venetoclax in combination with increasing cytarabine doses plus mitoxantrone to define the safety profile and MTD of cytarabine in subjects with a histologically or cytologically confirmed acute myeloid leukemia who are …
Phase 1/2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to outperform chemo for advanced bladder cancer
Disease control OngoingThis study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this …
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Massive UK trial seeks best drugs to beat pneumonia and COVID-19
Disease control Recruiting nowRECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convale…
Phase 3 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC